Post-market access service platform_Zhongguancun Shuimu Medical Technology Service Group

HOME PAGE > CORPROATE SERVICES > Post-market access service platform

Medical Device Market Access Service Platform

A leading provider of innovative services for the healthcare industry.

About Us Core Business Core Advantages Contact Us

Medical Device Market Access Service Platform

Beijing Shuimu Jingzhi Medical Technology Innovation Co., Ltd.

China’s first independent MedSim center.

Beijing Shuimu Jingzhi Medical Technology Innovation Co., Ltd., China’s first independent third-party scenario-based medical simulation training center, fills a domestic gap in this field with advanced facilities and professional services. Our core business spans: Clinical Application Evaluation, Pricing & Reimbursement (P&R) Market Access, Medical Training, and Preclinical/Animal Studies. The center houses 12 operating rooms that fully replicate real clinical settings, plus functional areas such as Radiology and Clinical Laboratory. It is equipped with 500+ real training devices and digital medical training solutions, creating a learning environment that closely mirrors clinical practice. We have established partnerships with multiple leading domestic and international MNCs, and we possess extensive resources across medicine, education, research, and industry. By building an end-to-end service system—“proof of concept → technology maturation → product iteration → application rollout”—we deeply integrate clinical, engineering, and market resources to help companies bridge the critical stages from R&D to commercialization.

As a leading enterprise committed to innovative services in healthcare, Shuimu Jingzhi focuses on empowering healthcare professionals through professional education, optimizing cost-management systems, and advancing the sector’s sustainable development. With a global perspective and deep local expertise, we provide end-to-end solutions for healthcare institutions, medical practitioners, and patients—helping elevate care quality and reshape industry value.

Core Service Areas

Clinical Application Evaluation

Translational Innovation Validation

Build an academic platform for medicine–engineering integration and translational innovation, assess the feasibility of technology R&D, and promote the translation of innovative technologies into practical outcomes.
Promotion of Innovative Technologies

Leverage official industry-association platforms to accelerate the dissemination and scaled adoption of new technologies through academic conferences, research projects, and training programs.
Facilitate Clinical Adoption

Validate the clinical value of innovations via animal studies and real-world evidence, support technology selection and iteration, and provide decision evidence for the market entry of new medical technologies.
Multi-Dimensional Professional Evaluation

Combine clinical data, technical verification, and expert review to build a multi-dimensional evaluation framework that optimizes hospital equipment planning and supports scientific research projects.

Pricing & Reimbursement (P&R) Market Access

Access Pathway Planning

Define the market-access pathway and potential bottlenecks. Develop the product’s registration name and intended use in line with access requirements; clarify reimbursement classification and core value propositions while preparing the supporting data package.
Health Insurance Reimbursement

Interpret reimbursement policies and formulate payer strategy per requirements. Assist enterprises in applying for benefit coverage for innovative technologies and in upgrading reimbursement levels where applicable.
Hospital Access

Support entry of new products into hospitals, address hospital-level governance/restriction controls, and build an expert platform for hospital management stakeholders.
Pricing & “Consumables-Excluded” Filings

Analyze policies on procedure pricing and consumables-excluded billing, and conduct feasibility assessments. Help hospitals submit applications for new medical service items and for consumables-excluded billing.
Health Technology Assessment (HTA)

Use diversified evaluation methods to comprehensively assess a device’s clinical and economic value, providing evidence to support pricing, reimbursement, and hospital formulary/access decisions.

Animal Studies

Feasibility Study

Safety Study

Efficacy Study

For certain products such as innovative medical devices, feasibility studies are used to identify any additional risks introduced by design choices, followed by corresponding risk-management activities to refine and improve the product. Evidence from feasibility animal studies can serve as supporting documentation for design justification.
Safety studies are a primary purpose of animal testing: they evaluate the impact of a finalized design on organism safety while performing its intended function. These may include short-term tests (e.g., immediate assessments of operational safety) as well as medium/long-term tests (e.g., aligned with the degradation period of an implant).
Although differences between animals and humans may exist in effectiveness/efficacy assessments, in some cases well-designed animal studies can support a product’s effectiveness/performance. Examples include evaluating the anti-adhesion performance of resorbable anti-adhesion devices, assessing the ability of tissue-repair materials to guide regeneration and remodeling, and evaluating osseointegration for porous-coated joint devices or 3D-printed porous implants.

Key Strengths

Access to Top Experts

Top 3 Hospitals Nationwide

0

+
Specialties Covered

0

+
Clinical & Non-clinical Expert Pool

0

+

Nationwide Academic Network Coverage

Med–Engineering Events

Held to Date

0

+
Top-Hospital Network

Coverage

0

+
Device Value Assessment

Research Projects

0

+
Tertiary Hospital Decision-Makers

Precise Reach

0

+

Strategic Sharing Platform

We provide an exhibition space, in partnership with innovative med-tech companies, for rehabilitation products and consumer medical products aimed at non-medical users. The showroom is regularly refreshed with new iterations of exhibits and complemented by a program of themed exchange events.

We have established application-promotion partnerships with Fortune Global 500 healthcare and medtech companies, including Johnson & Johnson, Medtronic, Boston Scientific, BD (Becton, Dickinson and Company), Mindray, Kangji Medical, SonoScape, and Bluesail Surgical.

Professional-Grade Facilities

Smart Conference Rooms

8–100 ppl
OR↔venue two-way live.
Simulation Labs

Endoscopy
ECG/vascular
Oph/Ortho specimens.
Real OR Setup

Hybrid OR (DSA/VCT/Robotics)
8 parallel platforms.

Three-in-One Experimental Platform

Industry-Leading Three-in-One Platform for Clinical Training, Research Experiments, and International Certification
A structured training curriculum validated by 20,000+ participants, delivered by senior certified instructors.
20 years of experience in advanced minimally invasive (human medicine) training, translated into scalable programs; 5 years of veterinary specialty training system validation.

Shuimu Jingzhi Post-Market Access, Evaluation & Training Integrated Platform

Med-Tech Academic Platform

Market Access Think Tank

Data-Driven Clinical Evaluation

Innovative Care Training Base

Leveraging resources from national-level industry associations, we have built an academic outreach network covering 30+ provinces and municipalities across China, carrying out academic conferences, research projects, and training programs. We have established a professional, third-party academic promotion center of over 5,000 m², providing a shared exhibition space in the healthcare market for showcasing innovative products.

Anchored in technology-driven value and leveraging expert resources from all stakeholders across the access pathway, we provide end-to-end market access planning for medical device companies throughout the product lifecycle. From product development and policy access to commercial rollout, our targeted strategies cover the full process—including reimbursement/insurance code applications, pricing consultation, and more—to de-risk and accelerate market entry for innovative technologies.

With a technology-value–centered approach and expert resources from all stakeholders along the access pathway, we provide full-lifecycle market access planning for medical device companies in China. From product development and policy access to commercial rollout, our targeted strategies cover the entire process—including health-insurance code applications, pricing consulting, and more—to safeguard and accelerate market entry for innovative technologies.

Leveraging authoritative industry associations and a top-tier faculty of expert instructors, we conduct preclinical validation and post-market training in innovative surgical techniques for physicians—using ex vivo perfused organ models and in vivo animal studies. This enables standardized, evidence-based dissemination of new techniques and creates a distinct competitive advantage in the field of technical normalization and promotion.

Three Key Objectives

Improved Outcomes
Enhanced Experience
Reduced Costs
Three Core Services

Improved Outcomes
Enhanced Experience
Reduced Costs

Shuimu Jingzhi

Technology Integration

Cutting-Edge Disciplines

Frontier Technologies

Innovative Therapies

End-to-End Market Access Planning & Advisory Think Tank

Closed-Loop Market Access Services

Policy insights & pricing strategy at the product-development stage
Reimbursement coding & pricing applications
Green channel for innovative devices (priority/fast-track access)
Payment Enablement & Safeguard

Hospital research onboarding, public payer (medical insurance) reimbursement, commercial insurance coverage.
Leveraging extensive global regulatory, policy, and market-access experience, we help enterprises meet the reimbursement era with high standards and de-risk commercialization for medical devices.
Health Insurance Data Assets

A dynamic policy repository covering 30 provinces/municipalities
100+ health-economics evaluation cases for innovative medical devices

Data-Driven Clinical Application Evaluation Center

China’s First Medical-Device Clinical Evaluation & Application Promotion Center

A multi-dimensional evaluation framework covering clinical effectiveness, health economics, and technical performance.
Includes the following medical science & technology evaluation consensuses

Expert Consensus on the Comprehensive Evaluation of Ultrasonic Surgical Systems
Expert Consensus on the Comprehensive Value Assessment of Electrophysiology Medical Devices
Expert Consensus on the Comprehensive Value Assessment of Medical Devices
Research and consensus frameworks covering: Day-Surgery Operating Room Equipment, Medical Dressings, Hemostatic Materials, Left Atrial Appendage Occlusion (LAAO), Medical Foam Dressings Comprehensive Evaluation System, Comprehensive Value Assessment of High-Value Medical Devices, and Application Evaluation of Emergency Laboratory Equipment, among others.
Objective Evaluation & Validation

We provide clinical needs collection and validation, clinical study design, preclinical (animal) testing and evaluation services, and post-market clinical evaluation studies. These generate decision evidence for hospital market access and volume-based procurement (VBP).

Innovative Diagnostics & Therapeutics Training and Education Base

Shuimu Jingzhi operates a 2,000 m² animal experiment center built to international standards, equipped with 5 operating rooms and 12 operating tables. The center supports multiple types of in vivo procedures—including surgical robotics and endoscopy—and conducts animal studies for Class II and Class III medical devices, evaluating feasibility, effectiveness, and safety.

As one of China’s largest third-party training platforms for innovative medical technologies, we validate product performance through animal studies and deliver standardized clinical procedure training to shorten the learning curve and strengthen clinical technical support. Backed by a top-tier expert faculty and collaboration with 100+ leading Class III Grade A hospitals—including the PLA General Hospital (301 Hospital), Peking Union Medical College Hospital (Xiehe), Beijing Friendship Hospital, and Beijing Anzhen Hospital—we have established shared training platforms in surgery, neuroscience, and cardiovascular disciplines.